EMA Authorised: Ebvallo (tabelecleucel) — Pierre Fabre Medicament

View source ↗

Summary

The EMA authorised Ebvallo (tabelecleucel) for lymphoproliferative disorders; the therapy is developed by Pierre Fabre Medicament and designated an orphan medic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoproliferative Disorders

Drugs mentioned

• Ebvallo (tabelecleucel)

Snippet

Status: Authorised. Therapeutic area: Lymphoproliferative Disorders. MAH: Pierre Fabre Medicament. Decision date: 18/11/2025. Orphan medicine